Last reviewed · How we verify
RPH-051
RPH-051 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels.
RPH-051 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels. Used for Psoriasis, Atopic dermatitis.
At a glance
| Generic name | RPH-051 |
|---|---|
| Sponsor | R-Pharm |
| Drug class | PDE4 inhibitor |
| Target | PDE4 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
PDE4 inhibition leads to accumulation of cyclic adenosine monophosphate (cAMP) in immune and inflammatory cells, suppressing the release of pro-inflammatory cytokines and chemokines. This mechanism is intended to reduce excessive inflammatory responses in autoimmune and inflammatory conditions. The selective PDE4 inhibition aims to provide anti-inflammatory efficacy while potentially minimizing off-target effects associated with broader phosphodiesterase inhibition.
Approved indications
- Psoriasis
- Atopic dermatitis
Common side effects
- Nausea
- Diarrhea
- Headache
- Vomiting
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RPH-051 CI brief — competitive landscape report
- RPH-051 updates RSS · CI watch RSS
- R-Pharm portfolio CI